rabbit anti smo  (Santa Cruz Biotechnology)

Journal: Frontiers in Immunology

Article Title: Molecular characteristics and cancer immunity of LRP1B and its relationship with the Hedgehog signaling pathway in colorectal cancer

doi: 10.3389/fimmu.2025.1567102

Figure Lengend Snippet: Association of LRP1B with the Hedgehog signaling pathway in CRC. (A) Western blot analysis of SHH, PTCH1, PTCH2, SMO, SUFU, GLI1, CHEK2, E2F1, Cyclin D1, Cyclin B1, p53, CDK1, CDK2, p21, BCL-2, and β-actin in LS180 and HCT116 cells with or without knockdown. (B) Potential mechanism of LRP1B in the suppression of CRC.

Article Snippet: The following primary antibodies were purchased: SHH (1:1,000, 2207T, Cell Signaling Technology, Shengxia Road, Pudong New Area, Shanghai, China), PTCH1 (1:1,000, 2468T, Cell Signaling Technology, USA), PTCH2 (1:1,000, 2470T, Cell Signaling Technology, USA), SMO (1:1,000, 92981T, Cell Signaling Technology, USA), SUFU (1:1,000, 2520T, Cell Signaling Technology, USA), GLI1 (1:1,000, 3538T, Cell Signaling Technology, USA), CHEK2 (1:1,000, 13954-1-AP, Proteintech, Chicago, USA), E2F1 (1:200, sc-251, Santa Cruz Biotechnology, USA), Cyclin D1 (1:1,000, 2978S, Cell Signaling Technology, USA, Jianye Road Pudong New District, Shanghai, China), Cyclin B1 (1:1,000, 12231S, Cell Signaling Technology, USA), p53 (1:1,000, 2527S, Cell Signaling Technology, USA), CDK1 (1:2,000, 19532-1-AP, Proteintech, Chicago, USA), CDK2 (1:1,000, 2546S, Cell Signaling Technology, USA), p21 (1:1000, 2947S, Cell Signaling Technology, USA), BCL-2 (1:1,000, 15071S, Cell Signaling Technology, USA), and β-actin (1:2,000, 20536-1-AP, Proteintech, Chicago, USA).

Techniques: Western Blot, Knockdown